Several medications are now advancing through clinical trials for eating disorders, and the one generating the most excitement among researchers is metreleptin, a synthetic form of the hormone leptin, which is showing striking results in anorexia nervosa — a condition that has never had a single FDA-approved drug treatment. In case reports and early studies, metreleptin has produced rapid improvements in the rigid thinking patterns, obsessive food-related cognition, and emotional disturbances that make anorexia so resistant to conventional therapy. A phase 2, placebo-controlled trial with 50 participants launched in 2024, with results expected in early 2026, and the psychiatric community is watching closely. But metreleptin is not the only candidate worth paying attention to. Solriamfetol is in a large phase 3 trial for binge eating disorder, psilocybin has cleared its first safety hurdle for anorexia, and GLP-1 receptor agonists like semaglutide are being studied for their effects on binge eating behaviors.
This matters for brain health because eating disorders are fundamentally neuropsychiatric conditions — they reshape neural circuits involved in reward, impulse control, and cognitive flexibility, and their consequences ripple into dementia risk, cognitive decline, and long-term brain structure changes. This article covers what each of these medications does, where the evidence stands, what the limitations are, and why the treatment gap remains so wide. The scale of the problem is staggering. Approximately 28.8 million Americans — about nine percent of the population — will struggle with an eating disorder in their lifetime, and these conditions kill roughly 10,200 people per year in the United States, one death every 52 minutes. Despite that burden, only two medications have ever received FDA approval for any eating disorder: fluoxetine for bulimia nervosa and lisdexamfetamine for binge eating disorder. For anorexia nervosa, the deadliest psychiatric illness by mortality rate, the pharmacological cupboard has been completely bare.
Table of Contents
- Why Has Finding an Effective Eating Disorder Medication Been So Difficult?
- Metreleptin and the Leptin Hypothesis in Anorexia Nervosa
- Solriamfetol and the Next Generation of Binge Eating Treatments
- Psilocybin, Ketamine, and the Psychedelic Approach to Rigid Thinking
- GLP-1 Medications and the Risks of Overpromising
- Why the Brain Health Connection Matters
- What the Next Five Years May Bring
- Conclusion
- Frequently Asked Questions
Why Has Finding an Effective Eating Disorder Medication Been So Difficult?
The short answer is that eating disorders hijack multiple brain systems simultaneously — reward processing, anxiety circuitry, habit formation, interoception, and cognitive flexibility — and no single drug mechanism has been able to address that complexity. A systematic search of the U.S. Clinical Trials Registry covering 2010 to 2025 identified 43 eligible phase I through IV trials across eating disorder diagnoses: 12 for anorexia nervosa, 27 for binge eating disorder, 2 for bulimia nervosa, and 2 for rumination disorder. Out of all those trials, only one new approval emerged. That ratio tells you how difficult this therapeutic space has been. Compare this to depression or anxiety, where dozens of approved medications exist across multiple drug classes.
The difference is partly biological — anorexia involves a starvation state that alters brain chemistry in ways that confound drug testing — and partly structural. Eating disorder research has been chronically underfunded relative to the disease burden, clinical trial recruitment is difficult because many patients resist treatment, and the endpoints are hard to define. What counts as success? Weight restoration? Reduced binge frequency? Improved cognitive rigidity? Each of those targets may require a different pharmacological approach. The brain health implications are significant. Chronic malnutrition in anorexia leads to gray matter volume loss, white matter changes, and cognitive deficits that can persist even after weight recovery. Binge eating disorder is associated with impaired executive function and reward-processing abnormalities that overlap with patterns seen in addiction and early neurodegeneration. Finding medications that address these conditions is not just a psychiatric priority — it is a neurocognitive one.
Metreleptin and the Leptin Hypothesis in Anorexia Nervosa
Metreleptin works by replacing leptin, a hormone produced by fat cells that plummets to dangerously low levels during starvation. Leptin does far more than regulate appetite — it modulates mood, cognition, reward sensitivity, and reproductive function. The hypothesis driving metreleptin research is that many of the psychiatric symptoms clinicians attribute to anorexia itself — the obsessive thinking, emotional flatness, hyperactivity, and rigid behaviors — are actually downstream effects of severe leptin deficiency on the brain. Restore leptin signaling, and those symptoms may loosen their grip enough for patients to engage meaningfully with psychotherapy and nutritional rehabilitation. The early evidence is compelling, though still limited. A prior open-label study documented what researchers described as “rapid onset of beneficial cognitive, emotional, and behavioral effects” with short-term metreleptin treatment. A 2025 case report published in European Child and Adolescent Psychiatry detailed improvements in eating disorder psychopathology, obsessive-compulsive symptoms, depression, and non-suicidal self-injury in a 17-year-old female patient treated off-label with metreleptin.
These are exactly the entrenched symptoms that make anorexia so treatment-resistant and so damaging to developing brains. However, there is an important caveat. Case reports and open-label studies cannot establish causation, and the placebo effect in eating disorder treatment is substantial. The phase 2 randomized controlled trial now underway — with 50 participants, placebo control, and blinding — will provide much stronger evidence. If metreleptin works as the case reports suggest, it could become the first medication specifically approved for anorexia nervosa. If the results are ambiguous, it will join a long list of promising candidates that did not survive rigorous testing. Clinicians and families should be hopeful but measured.
Solriamfetol and the Next Generation of Binge Eating Treatments
For binge eating disorder, the most common eating disorder in the United States, the treatment landscape may be about to shift. Solriamfetol, marketed as Sunosi for excessive daytime sleepiness, is being tested in a large phase 3 trial called ENGAGE. This randomized, double-blind, placebo-controlled, multicenter study enrolled 450 patients divided equally among three arms — 150 milligrams, 300 milligrams, and placebo — for a 12-week treatment period. The primary endpoint is change in the number of binge-eating episodes per week. First patient screening began in March 2024, and the trial is being run by Axsome Therapeutics. Solriamfetol is a dopamine and norepinephrine reuptake inhibitor that also acts as a TAAR1 agonist, giving it a mechanism of action that partially overlaps with lisdexamfetamine but with potentially different tolerability and duration characteristics.
The dopamine reuptake inhibition is relevant because binge eating is increasingly understood as a disorder of reward circuitry — the same networks implicated in addiction and certain neurodegenerative conditions. As of March 2026, results from the ENGAGE trial have not been publicly released, so its efficacy remains unconfirmed. What makes solriamfetol particularly interesting is the specific limitation of the current standard treatment. Lisdexamfetamine, the only FDA-approved medication for binge eating disorder, has a well-documented real-world problem: its appetite-suppressing effects tend to wear off by evening, while many patients report their highest binge risk at night. The crash that follows can leave patients fatigued and irritable — conditions that actually increase vulnerability to binge episodes. A Rutgers study found mixed results when examining lisdexamfetamine in real-world use, underscoring the gap between clinical trial performance and day-to-day effectiveness. If solriamfetol can offer a different pharmacokinetic profile or more sustained effect, it could fill a genuine clinical need.
Psilocybin, Ketamine, and the Psychedelic Approach to Rigid Thinking
Two psychedelic or psychedelic-adjacent compounds are being studied for anorexia nervosa, and their rationale connects directly to brain health. Anorexia is characterized by extreme cognitive rigidity — the inability to shift mental sets, consider alternative perspectives, or break free from entrenched thought patterns about food, body, and control. This rigidity maps onto neural patterns in the prefrontal cortex and default mode network that overlap with changes seen in obsessive-compulsive disorder and certain dementias. Psilocybin — the active compound in psychedelic mushrooms — showed initial promise in a phase 1, open-label feasibility study published in Nature Medicine in July 2023. Researchers administered a single 25-milligram dose of synthetic psilocybin with psychological support to females with anorexia nervosa and found it to be safe and tolerable, with all adverse events mild and transient. A 2025 systematic review identified six registered clinical trials of psilocybin for eating disorders, with sample sizes ranging from 21 to 40 participants.
Two trials have completed but not yet published results, and one has an estimated completion date of June 2029, indicating this is still a long-horizon research area. Ketamine, meanwhile, is being tested at UCSF in medically hospitalized adolescents and young adults with anorexia. The hypothesis is that intravenous ketamine increases cognitive flexibility and improves the ability to learn positive associations with food — essentially helping the brain form new pathways that compete with the rigid, illness-maintaining patterns. The tradeoff with both compounds is that they require careful medical supervision, carry dissociative side effects, and involve psychological support infrastructure that may limit scalability even if the drugs prove effective. They are not likely to become take-home prescriptions. But for treatment-resistant cases where cognitive rigidity is the primary barrier, they may offer something no existing medication can.
GLP-1 Medications and the Risks of Overpromising
GLP-1 receptor agonists like semaglutide and liraglutide have dominated health headlines for weight loss, and inevitably their effects on eating behaviors have drawn research attention. A rapid review published in January 2025 screened 1,597 records and ultimately included 25 studies encompassing 8,997 participants examining GLP-1 medications and eating behaviors. The findings showed that binge eating episodes and prevalence reduced following treatment with liraglutide and semaglutide, respectively. However, the results are described as mixed by experts in the field, and there is currently no FDA approval for any GLP-1 medication for an eating disorder. The National Association of Anorexia Nervosa and Associated Disorders has cautioned specifically about the risks of misuse — these drugs suppress appetite through mechanisms that could worsen restrictive eating disorders or be used to facilitate the very behaviors that clinicians are trying to treat.
For someone with binge eating disorder and comorbid obesity, a GLP-1 agonist might offer genuine dual benefit. For someone with a restrictive subtype, or with a history that oscillates between bingeing and restriction, the same drug could be dangerous. This is a critical distinction that gets lost in popular coverage. The brain health angle matters here too: GLP-1 receptors are expressed throughout the central nervous system and are being studied for neuroprotective effects in Alzheimer’s disease, but the interaction between appetite suppression, nutritional status, and long-term cognitive health in eating disorder patients is entirely unstudied. Clinicians treating eating disorders have reason to be cautious, even as the drugs generate legitimate scientific interest for other neurological conditions.
Why the Brain Health Connection Matters
Eating disorders are not just psychiatric conditions — they are brain conditions with measurable neurological consequences. Anorexia nervosa causes cortical thinning, reduced hippocampal volume, and disrupted connectivity in networks responsible for emotional regulation and decision-making. Some of these changes reverse with sustained recovery, but studies suggest that certain cognitive deficits may persist for years, particularly in patients with prolonged illness duration.
Binge eating disorder, meanwhile, is associated with inflammation, metabolic disruption, and reward-processing impairments that share pathways with neurodegenerative disease. This is why the medication pipeline matters beyond the eating disorder community. Each of these compounds — metreleptin restoring hormonal signaling, psilocybin and ketamine increasing neural plasticity, GLP-1 agonists engaging central appetite and reward circuits — is fundamentally a brain intervention. Progress in eating disorder pharmacology will almost certainly yield insights relevant to cognitive aging, neuroplasticity, and brain resilience.
What the Next Five Years May Bring
The convergence of multiple clinical trials reaching completion between 2026 and 2029 means the eating disorder treatment landscape could look substantially different by the end of this decade. The metreleptin phase 2 results, expected imminently, will be the first rigorous test of the leptin hypothesis in anorexia. The solriamfetol phase 3 data will determine whether binge eating disorder patients gain a meaningful alternative to lisdexamfetamine. And the accumulating psilocybin data will clarify whether psychedelic-assisted therapy has a role in the most treatment-resistant cases.
What will not change quickly is the structural problem: 43 clinical trials over 15 years producing only one new approval reflects systemic underinvestment. Even if every currently promising candidate succeeds, the field will still have fewer approved options than most psychiatric conditions with comparable disease burden. The medications showing real promise today represent hard-won progress, but the gap between what patients need and what pharmacology can currently offer remains wide. Closing it will require not just successful trials but sustained funding, better trial design for complex psychiatric conditions, and recognition that eating disorders are serious brain illnesses deserving of the same research intensity directed at depression, psychosis, and neurodegeneration.
Conclusion
The eating disorder medication pipeline is more active and more scientifically grounded than at any point in the past two decades. Metreleptin targets the hormonal disruption that may drive many of anorexia’s most intractable psychiatric symptoms. Solriamfetol could address the real-world limitations of the only approved binge eating medication. Psilocybin and ketamine are testing whether increased neural plasticity can break the cognitive rigidity that keeps patients locked in illness.
And GLP-1 agonists, despite significant caveats, are opening new research questions about appetite regulation, reward circuits, and brain health. For families and clinicians navigating eating disorder treatment today, the practical reality is that these medications are not yet available as standard options. The most important steps remain early intervention, evidence-based psychotherapy, nutritional rehabilitation, and close medical monitoring. But the clinical trials now reaching their endpoints offer genuine cause for cautious optimism — the kind of progress that comes from rigorous science rather than hype. For those in the brain health community, these developments are a reminder that eating disorders are neuropsychiatric conditions with consequences that extend well beyond weight and eating behavior, and that advances in their treatment have implications for understanding cognitive resilience, neural plasticity, and brain recovery.
Frequently Asked Questions
Is there any FDA-approved medication for anorexia nervosa?
No. As of 2026, there is no FDA-approved medication for anorexia nervosa. The only two eating disorder medications with FDA approval are fluoxetine (Prozac) for bulimia nervosa and lisdexamfetamine (Vyvanse) for binge eating disorder. Metreleptin is the most advanced candidate for anorexia, with a phase 2 trial expected to report results in early 2026.
What is metreleptin and how does it work for anorexia?
Metreleptin is a synthetic version of leptin, a hormone produced by fat cells that drops to very low levels during starvation. Beyond regulating appetite, leptin affects mood, cognition, and reward processing in the brain. By restoring leptin levels, metreleptin may reduce the rigid thinking, obsessive behaviors, and emotional disturbances that characterize anorexia nervosa. Early case reports have shown rapid improvements, but the randomized controlled trial results are still pending.
Can Ozempic or other GLP-1 drugs treat binge eating disorder?
GLP-1 receptor agonists like semaglutide and liraglutide have shown some effect on reducing binge eating episodes in research, but results are described as mixed and no GLP-1 medication has FDA approval for any eating disorder. Experts also caution that these drugs carry risks of misuse, particularly in patients with restrictive eating histories. They should not be used off-label for eating disorders without careful specialist oversight.
Is psilocybin safe for people with anorexia?
A phase 1 feasibility study published in Nature Medicine in 2023 found that a single 25-milligram dose of synthetic psilocybin, administered with psychological support, was safe and tolerable in females with anorexia nervosa. All adverse events were mild and transient. However, this was a small, open-label study — not a definitive safety assessment. Multiple larger trials are underway, with some not expected to complete until 2029.
Why does Vyvanse not work well for some people with binge eating disorder?
Lisdexamfetamine (Vyvanse) suppresses appetite, but its effects typically wear off by evening. Since many people with binge eating disorder experience their strongest urges to binge at night, the medication may not provide coverage when it is most needed. The post-medication crash can also cause fatigue and irritability, which may actually increase binge vulnerability. A Rutgers study confirmed mixed results in real-world settings compared to controlled clinical trials.
How do eating disorders affect long-term brain health?
Eating disorders cause measurable changes in brain structure and function. Anorexia nervosa leads to cortical thinning, reduced hippocampal volume, and disrupted connectivity in brain networks involved in emotional regulation and decision-making. Some changes reverse with recovery, but cognitive deficits may persist for years in patients with prolonged illness. Binge eating disorder is associated with inflammation and reward-processing impairments that share pathways with neurodegenerative disease.
